Canada markets open in 2 hours 6 minutes
  • S&P/TSX

    20,265.37
    +83.93 (+0.42%)
     
  • S&P 500

    4,283.74
    +9.70 (+0.23%)
     
  • DOW

    33,999.04
    +18.72 (+0.06%)
     
  • CAD/USD

    0.7699
    -0.0028 (-0.37%)
     
  • CRUDE OIL

    88.63
    -1.87 (-2.07%)
     
  • BTC-CAD

    27,970.97
    -2,699.15 (-8.80%)
     
  • CMC Crypto 200

    512.33
    -45.40 (-8.14%)
     
  • GOLD FUTURES

    1,764.00
    -7.20 (-0.41%)
     
  • RUSSELL 2000

    2,000.73
    +13.41 (+0.68%)
     
  • 10-Yr Bond

    2.8800
    0.0000 (0.00%)
     
  • NASDAQ futures

    13,381.50
    -141.75 (-1.05%)
     
  • VOLATILITY

    20.83
    +0.93 (+4.67%)
     
  • FTSE

    7,543.00
    +1.15 (+0.02%)
     
  • NIKKEI 225

    28,930.33
    -11.81 (-0.04%)
     
  • CAD/EUR

    0.7657
    +0.0002 (+0.03%)
     

CareDx Wins $44.9 Million in Damages in False Advertising Trial

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com -- Caredx Inc (NASDAQ:CDNA) announced Monday evening that the company has won its false advertising case against Natera Inc (NASDAQ:NTRA).

CareDx won $44.9 million in damages. Shares rose 8.8% after the announcement.

The jury determined that Natera intentionally misled the transplant community by engaging in false advertising and promoting its Prospera kidney transplant rejection assessment test.

CareDx was awarded $21.2 million compensatory damages and $23.7 million punitive damages. CareDx said "overwhelming evidence" emerged that Natera's senior executives knew of the unscientific and unreliable statements made to market Prospera.

"The jury found Natera liable for false advertising based on Natera's false comparisons of its kidney transplant assessment test, Prospera, to CareDx's market-leading AlloSure technology," CareDx said in its press release.

Natera stock is down 16%.

Related Articles

CareDx Wins $44.9 Million in Damages in False Advertising Trial

U.S. senators urge probe of Live Nation's 'exorbitant fees' for tickets

Lilly, Novartis join drugmakers in scaling back operations in Russia

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting